07:36 AM EDT, 03/17/2025 (MT Newswires) -- Perspective Therapeutics ( CATX ) said Monday the first patient was dosed in a new cohort of its phase 1/2a trial evaluating the safety of targeted alpha-particle therapy [212Pb]VMT01 in patients with histologically confirmed melanoma and positive melanocortin 1 receptor imaging scans.

Patients in the new cohort are receiving the therapy in combination with nivolumab, a PD-1 blocking antibody developed and marketed by Bristol Myers Squibb ( BMY ) as Opdivo, compared to earlier cohorts where the patients received it as monotherapy, the company said.

The data from this part of the study will enable the company to further understand "how lower-dose radiopharmaceuticals can be optimized in combination with immunotherapies," Perspective CEO Thijs Spoor said.